Abstract 5764
Background
BT1718 contains a constrained bicyclic peptide with high affinity and selectivity for cell surface target MT1-MMP (MMP14) linked to a toxin (DM1) via a cleavable disulphide linker. BT1718 has demonstrated significant anti-tumor activity in preclinical studies in tumors that express MT1-MMP. Following intravenous (IV) administration to preclinical species, BT1718 exhibited PK typical of a BTC. We report clinical progress on QW and BIW dosing, plasma and tumor PK results.
Methods
This is a first in human, multicenter, dose escalation study in advanced solid tumor pts with the aims of establishing the recommended phase 2 dose (RP2D) for QW & BIW IV BT1718 dosing (3 out of every 4 weeks per cycle), and exploratory PK. Following determination of RP2Ds, expansion cohorts will enroll to further explore efficacy, tolerability and PD of BT1718 in ∼70 pts with MT1-MMP expressing tumors such as NSCLC and TNBC.
Results
24 pts were enrolled with various types of solid tumors across both dose escalation cohorts (see table). BIW RP2D was determined as 7.2 mg/m2. The 2 pts with DLTs at 9.6 mg/m2 BIW experienced grade 3 increased GGT or fatigue. QW dose escalation continues at 20 mg/m2. Mean number of cycles received = 2.3 months (N = 24), with no objective responses observed to date in this unselected population. Consistent with preclinical data, preliminary clinical PK results with BT1718 confirm moderate plasma clearance (∼10 mL/min/kg) linear with dose, a volume of distribution similar to extracellular fluid (∼0.20 L/kg) and a t1/2 of ∼0.3 h. Analysis of pts biopsy samples confirms distribution of DM1 in tumors at similar concentrations observed in mouse xenograft models. Results will be updated at time of presentation.Table:
464P
BT1718 Dose (mg/m2) | Twice weekly schedule (BIW) | Once weekly schedule (QW) | ||
---|---|---|---|---|
DLT evaluable pts | DLTs | DLT evaluable pts | DLTs | |
0.6 | 1 | 0 | NA | NA |
1.2 | 1 | 0 | NA | NA |
2.4 | 1 | 0 | NA | NA |
4.8 | 1 | 0 | NA | NA |
7.2 | 6 | 0 | NA | NA |
9.6 | 4 | 2 | 3 | 0 |
15 | NA | NA | 3 | 0 |
20 | NA | NA | 2 | 0 |
Conclusions
BT1718 is a first in class BTC which is generally well tolerated at the present dose level. Current plasma and tumor PK data are consistent with proposed preclinical mechanism of tumor targeted toxin delivery.
Clinical trial identification
NCT03486730.
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research UK.
Funding
Cancer Research UK and BicycleRD Limited.
Disclosure
N. Cook: Advisory / Consultancy: Tarveda Therapeutics; Advisory / Consultancy: Epigene Therapeutics. U. Banerji: Advisory / Consultancy: Astellas; Advisory / Consultancy: Novartis; Advisory / Consultancy: Karus Therapeutics; Advisory / Consultancy: Phoenix ACT; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Astex; Advisory / Consultancy: Vernalis; Research grant / Funding (institution), ONX-0801: funding for investigator-initiated Phase I trial: Onyx Pharmaceuticals; Research grant / Funding (institution), ONX-0801: funding for investigator-initiated Phase I trial: BTG International; Research grant / Funding (institution), RAF/MEK: funding for investigator-initiated Phase I trial: Chugai; Research grant / Funding (institution), TAX-TORC: funding for investigator-initiated Phase I trial: AstraZeneca; Research grant / Funding (institution), FRAME: funding for investigator-initiated Phase I trial: Verastem; Full / Part-time employment, ICR is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF and CHK1: Institute of Cancer Research. J. Evans: Speaker Bureau / Expert testimony: BMS, Eisai, Bayer, Roche, Celgene, MSD; Officer / Board of Directors, Committee Member: Genmab (chair), BMS; Advisory / Consultancy: Karus Therapeutics; Research grant / Funding (self): AstraZeneca, Basliea, BMS, Bayer, Celgene, MSD, MiNa therapeautics, Roche, Medicina, Pfizer, Sierra, Verastem, Lilly, Eisai, NuCana, GSK, Novartis, Immunocore, Bicycle Therapeutics, Haloxyme, Berg, J&J, CytomX, BeiGene, Vertex, Plexxikon, BioLine Rx, Athe; Leadership role, Non-remunerated: Cancer Research UK, NCRN, Breast Cancer Now, Pancreatic Cancer Research Fund, EORTC GI group member, British Council of Cancer, Wales Clinical Trial Unit, ILCA; Non-remunerated activity/ies, Member: BACR, EACT, ACP, ESMO, ASCO, AACR. A. Biondo: Full / Part-time employment, ICR is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF and CHK1: Institute of Cancer Research. P. Jeffrey: Full / Part-time employment: BicycleRD Limited. M. Rigby: Full / Part-time employment: BicycleRD Limited. G. Bennett: Full / Part-time employment: BicycleRD Limited. S. Blakemore: Full / Part-time employment: BicycleRD Limited. All other authors have declared no conflicts of interest.
Resources from the same session
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract
4369 - Biomarker testing of lung cancer in Spain
Presenter: Delvys Rodriguez Abreu
Session: Poster Display session 1
Resources:
Abstract